8-K: Moleculin Biotech Highlights Annamycin's Potential in AML Treatment at KOL Event

Moleculin Biotech released the transcript of its Virtual Acute Myeloid Leukemia KOL event, emphasizing the potential of Annamycin as a non-cardiotoxic treatment option.

Summary

• Moleculin Biotech hosted a Virtual Acute Myeloid Leukemia (AML) Key Opinion Leader (KOL) event to discuss their drug candidate, Annamycin.
• The event featured key opinion leaders in AML, including physicians from MD Anderson Cancer Center, University of Bologna, and Atlantic Health System.
• Annamycin is a next-generation anthracycline designed to avoid multidrug resistance and cardiotoxicity, which are common issues with current anthracyclines.
• The company is initiating the MIRACLE trial, a Phase 3 pivotal trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML.
• Previous Phase 1/2 trials showed a 50% complete remission (CR) rate in second-line AML patients, which is significantly higher than the average 21% CR rate of currently approved second-line AML therapies.
• The MIRACLE trial will use an adaptive design with two different dosing regimens of Annamycin compared to a control arm using HiDAC (high-dose cytarabine) plus a placebo.
• The company expects to announce the first patient treated in the first quarter of 2025 and a peak at the data by the end of 2025, with a key unblinded data readout expected in mid-2026.
• The company believes that the consistent historical performance of the HiDAC control arm (17-18% CR rate) will allow for early indications of Annamycin's efficacy even with blinded data.

Sentiment

Score: 8

Explanation: The document presents a highly positive outlook for Annamycin, with strong efficacy data and a clear path to potential approval. The involvement of key opinion leaders and the FDA's acknowledgment of the drug's unique attributes further boost the positive sentiment. However, the company's low market cap and financing concerns temper the overall optimism slightly.

Positives

• Annamycin has shown a 50% complete remission rate in second-line AML patients, which is significantly higher than existing treatments.
• The drug is designed to be non-cardiotoxic, addressing a major limitation of current anthracyclines.
• Annamycin has demonstrated a lack of cross-resistance with other AML drugs, including cytarabine and Venetoclax.
• The FDA has acknowledged Annamycin's lack of cardiotoxicity, allowing for higher dosing in the Phase 3 trial.
• The MIRACLE trial has an adaptive design, allowing for early looks at the data and selection of the optimal Annamycin dose.
• The company has Orphan Drug and Fast Track designations for Annamycin, and patents through 2040.
• Key opinion leaders expressed enthusiasm for Annamycin's potential to address the unmet need in relapsed/refractory AML.
• The company expects to have some midpoint data by mid-2025 that will be indicative of the direction of the trial.

Negatives

• The company's market cap is considered low for a Phase 3 asset in the AML space.
• There are concerns about financing overhang, which is common for small biotech companies.
• The initial data is from a relatively small number of patients, and the Phase 3 trial is needed to confirm the results.
• The control arm of the MIRACLE trial, HiDAC, is not considered attractive by some researchers and patients.
• The company is still in the site selection mode for the MIRACLE trial, and the first patient is not expected to be treated until January 2025.

Risks

• The Phase 3 trial results may not replicate the positive results seen in earlier trials.
• The company may face challenges in recruiting patients for the MIRACLE trial.
• There is a risk of infection and other adverse events associated with chemotherapy treatments.
• The company may face challenges in securing funding for the Phase 3 trial and future development.
• The company may not be able to secure a development partner as quickly as they hope.

Future Outlook

The company anticipates the MIRACLE trial will lead to a new drug application approval for Annamycin in combination with cytarabine for the treatment of relapsed or refractory AML. They also plan to explore Annamycin in other leukemias, first-line treatments, and other cancers.

Management Comments

• Walter Klemp, CEO, stated that the company is baffled that their market cap is not higher given their Phase 3 asset in AML.
• Walter Klemp believes that the lack of focus on anthracyclines by investors makes Moleculin a hidden opportunity.
• Walter Klemp mentioned that the company expects to announce first patient treated in the first quarter of '25, and even to provide a peak at the data by the end of '25.
• Walter Klemp stated that the key unblinded data readout is expected in mid '26 and that's when development partners will likely be involved to a much greater extent.
• Walter Klemp stated that by mid '25, the company expects to have some midpoint data that will be indicative of the direction this trial is going.
• Paul Waymack, Senior Chief Medical Officer, stated that the FDA agreed that a Phase 3 trial could be constructed around using CR rates as the primary efficacy end point for a new drug application approval.

Industry Context

The announcement highlights the ongoing need for effective treatments in AML, particularly in the relapsed/refractory setting. While targeted therapies have gained attention, traditional chemotherapy agents like anthracyclines remain a cornerstone of treatment. Annamycin's potential to address cardiotoxicity and multidrug resistance could position it as a significant advancement in the field.

Comparison to Industry Standards

• The average complete remission rate for FDA-approved second-line AML therapies is around 21%, while Annamycin has shown a 50% CR rate in Phase 1/2 trials.
• The historical CR rates for HiDAC in relapsed/refractory AML patients are consistently around 17-18%, as demonstrated in two large, published studies.
• The company is comparing Annamycin to HiDAC, a well-established standard of care, which provides a reliable benchmark for assessing efficacy.
• The company is using a similar approach to the gilteritinib registration Phase 3 clinical trial, which randomized patients two to one or three to one to the experimental arm.

Stakeholder Impact

• Shareholders: The positive data and potential for approval could lead to increased share value.
• Patients: Annamycin offers a potential new treatment option for relapsed/refractory AML, with the potential for improved outcomes.
• Physicians: The drug's non-cardiotoxic nature and lack of cross-resistance could make it a valuable tool in their treatment arsenal.
• Employees: The success of the MIRACLE trial could lead to company growth and job security.

Next Steps

• Initiate the MIRACLE trial, a Phase 3 pivotal trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML.
• Announce the first patient treated in the first quarter of 2025.
• Provide a peak at the data by the end of 2025.
• Complete Part A of the MIRACLE trial and share unblinded data in mid-2026.
• Potentially seek development partners after the key unblinded data readout in mid-2026.
• Explore Annamycin in other leukemias, first-line treatments, and other cancers.

Key Dates

Keywords

Annamycin, Acute Myeloid Leukemia, AML, MIRACLE Trial, Anthracycline, Cardiotoxicity, Chemotherapy, Relapsed/Refractory AML, HiDAC, Clinical Trial, Oncology, Phase 3, FDA, Complete Remission, CR, MDR1, MCL1, Venetoclax, Cytarabine